Emergent BioSolutions Inc

Emergent BioSolutions Inc (NYSE: EBS) is a life sciences firm dedicated to offering preparedness and response solutions for public health threats, whether accidental, intentional, or naturally occurring. The company’s offerings consist of a portfolio of products, a product development portfolio, and a Bioservices portfolio. Its operations are divided into three segments: Commercial Products, MCM Products, and Services.

Recent Business and Financial Updates

• Financial Highlights (Q3 2024 vs. Q3 2023): In Q3 2024, the company reported total revenues of USD 293.8 million, marking a 9% increase compared to USD 270.5 million in Q3 2023. Net income surged by 144%, reaching USD 114.8 million, up from a net loss of USD 263.4 million in the same period last year. The net income per diluted share for Q3 2024 was USD 2.06, reversing the net loss per diluted share of USD (5.08) in Q3 2023. Adjusted net income also saw a significant turnaround, increasing by 236% to USD 76.2 million, compared to a loss of USD 56.2 million in Q3 2023. On a per share basis, the adjusted net income per diluted share improved by 226% to USD 1.37, compared to a loss of USD (1.09) per share in Q3 2023. Adjusted EBITDA for Q3 2024 rose by 432%, reaching USD 105.3 million, compared to USD 19.8 million in the prior year. Additionally, the company saw an improvement in its gross margin, with total segment gross margin percentage increasing to 57% in Q3 2024, up from 33% in Q3 2023. Segment adjusted gross margin percentage also rose to 59%, compared to 38% in the same period last year.
• Year-to-Date 2024 vs. Year-to-Date 2023: For the year-to-date (YTD) period ending September 30, 2024, total revenues amounted to USD 848.9 million, an increase of 10% compared to USD 772.7 million in YTD 2023. The net loss for YTD 2024 decreased by 78%, reaching USD 159.3 million, compared to a net loss of USD 711.0 million in YTD 2023. On a per diluted share basis, the net loss was USD (3.03), reflecting a 78% improvement over the prior year’s net loss of USD (13.97) per share. The company’s adjusted net loss also saw significant improvement, decreasing by 95% to USD (14.7) million, from a loss of USD (273.0) million in the previous year. Adjusted net loss per diluted share was USD (0.28), compared to USD (5.36) in YTD 2023. Adjusted EBITDA improved by 731%, totaling USD 162.1 million, up from a loss of USD (25.7) million in the prior year. The total segment gross margin for YTD 2024 increased slightly to 32%, compared to 31% in YTD 2023. The segment adjusted gross margin percentage rose to 46%, up from 33% in the previous year.
• Q3 2024 Business Updates: In Q3 2024, the company secured significant financial arrangements, including a USD 250 million term loan with OHA Agency, LLC, and a USD 100 million asset-backed loan facility with Wells Fargo Bank. The company also completed strategic asset sales, including the sale of RSDL® (Reactive Skin Decontamination Lotion) to SERB Pharmaceuticals for USD 75 million and the sale of its Baltimore-Camden manufacturing site for USD 35 million. Additionally, the company sold an underutilized warehouse at its Canton, MA facility for USD 7 million. It also received USD 50 million related to the resolution of a contractual dispute with Janssen Pharmaceuticals, Inc. and earned USD 30 million in development milestone payments from Bavarian Nordic as part of the sale of its Travel Health Business.
• Q3 2024 Financial Performance – Revenues: For Q3 2024, product sales revenue reached USD 269.5 million, an 8% increase compared to USD 249.8 million in Q3 2023. The revenue from NARCAN® Nasal Spray decreased by USD 46.8 million, or 33%, primarily due to the discontinuation of prescription NARCAN® after the OTC launch in Q3 2023, and lower Canadian retail sales, although offset by higher OTC NARCAN® sales. Revenues from Anthrax MCM products decreased by USD 21.5 million, or 65%, mainly due to the timing of sales related to CYFENDUS® and Anthrasil®, partially offset by higher BioThrax® sales. Smallpox MCM products saw a significant increase of USD 108.0 million, or 437%, driven by the timing of U.S. government purchases of ACAM2000® and VIGIV. Other products saw a decrease of USD 20.0 million, or 40%, primarily due to lower sales of BAT® and RSDL®, the latter of which was sold to SERB during Q3 2024. Bioservices revenue, which includes service and lease revenues, remained relatively stable at USD 14.3 million, up by 1% compared to Q3 2023.
• Capital Expenditures: In Q3 2024, capital expenditures amounted to USD 5.8 million, a 54% decrease from USD 12.6 million in Q3 2023. This decline was primarily attributed to lower product development activities across the company’s facilities.
• Q3 2024 Segment Results: The company operates through three main segments: Commercial Products, MCM Products, and Services. In the Commercial Products segment, revenues decreased by USD 46.8 million, or 33%, primarily due to lower sales of NARCAN® Nasal Spray. The segment’s gross margin also decreased by 41% to USD 48.1 million, primarily due to an unfavorable product mix for NARCAN®. The MCM Products segment saw a 62% increase in revenues, primarily driven by higher sales of smallpox-related products and favorable product mix. The gross margin for MCM Products improved significantly by 241%, reaching USD 120.2 million. In the Services segment, revenues were stable at USD 14.3 million, while the gross margin improved by 76%, largely due to lower overhead costs following the sale of the Camden facility.
• Updated Financial Forecast for Full Year 2024: The company has provided an updated financial outlook for 2024, with total revenues projected to be between USD 1.065 billion and USD 1.125 billion, slightly higher than the previous range of USD 1.050 billion to USD 1.125 billion. Net loss is expected to be between USD (203) million and USD (183) million, showing a significant improvement compared to the prior forecast of USD (314) million to USD (274) million. Adjusted net loss is anticipated to be between USD (50) million and USD (30) million, a notable reduction from the earlier forecast range of USD (115) million to USD (75) million. Adjusted EBITDA is expected to range from USD 180 million to USD 200 million, an improvement from the previous range of USD 140 million to USD 180 million. The company anticipates total segment adjusted gross margin percentage to fall between 43% and 45%, up from the prior estimate of 42% to 45%.
• Segment-Level Revenue and Key Assumptions: The company has outlined segment-level revenue expectations for 2024, with Commercial Products projected at USD 420 million to USD 430 million, down from the prior range of USD 450 million to USD 480 million. MCM Products revenue is forecasted to be between USD 510 million and USD 550 million, up from the previous range of USD 455 million to USD 490 million. Services revenue is expected to range from USD 105 million to USD 110 million, lower than the previous forecast of USD 120 million to USD 130 million. Key assumptions for 2024 include interest expense of approximately USD 75 million, R&D spending at about 7% of revenue, a weighted average fully diluted share count of 53 million, capital expenditures of USD 25 million, and depreciation & amortization at USD 109 million.

Technical Observation (on the daily chart):

EBS's stock price has faced resistance at significant levels and has subsequently decreased, indicating strong momentum that points to a potential consolidation phase with a bearish tendency. The 14-day Relative Strength Index (RSI) is falling below the midpoint, which further strengthens this negative perspective. Additionally, the stock price is currently trading below its 21-day simple moving averages, further bolstering the pessimistic outlook.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Watch’ rating has been given to Emergent BioSolutions Inc (NYSE: EBS) at the current market price of USD 9.43 as of December 03,2024 at 08:40 AM PST. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is December 03,2024 at 08:40 AM PST. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.